Paion Competitors and Similar CompaniesClear all
Paion's competitors and similar companies include Array BioPharma, ObsEva, Affimed N.V. and Avid Bioservices.
 Paion PAION is a biopharmaceutical company developing and commercializing drug candidates for diseases with substantial unmet medical needs. |  Array BioPharma Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. |  ObsEva ObsEva is a speciality biopharmaceutical company developing drugs for womens reproductive medicine. |  Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. |  Avid Bioservices Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company. | |
Founding Date | Founding Date 2000 | Founding Date 1998 | Founding Date 2012 | Founding Date 2000 | Founding Date 1981 |
Type | Type Public | Type Subsidiary | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Aachen, DE HQ Odense, DK Hoofddorp, NL Richmond, GB | Locations Boulder, US HQ Chicago, US Detroit, US Houston, US Miami, US New York, US Phoenix, US | Locations Plan-les-Ouates, CH HQ Boston, US Sacramento, US | Locations Heidelberg, DE HQ | Locations Tustin, US HQ |
Employees | Employees 3218% decrease | Employees 110 | Employees 811% decrease | Employees 76 | Employees 21114% increase |
Valuation ($) | Valuation ($) 49.7 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 52.5 m | Valuation ($) 649.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €33.2m (FY, 2022) | Revenue (est.) $173.8m (FY, 2018) | Revenue (est.) N/A | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) $139.9m (FY, 2024) |
Cost of goods | Cost of goods €382k (FY, 2022) | Cost of goods $59.4m (FY, 2018) | Cost of goods N/A | Cost of goods N/A | Cost of goods $132.6m (FY, 2024) |
Gross profit | Gross profit €33.4m (FY, 2022) | Gross profit $114.4m (FY, 2018) | Gross profit N/A | Gross profit €13m (FY, 2023) | Gross profit $7.3m (FY, 2024) |
Net income | Net income (€579k) (FY, 2022) | Net income ($147.7m) (FY, 2018) | Net income N/A | Net income (€105.9m) (FY, 2023) | Net income ($140.8m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 15.2m | Total funding raised N/A | Total funding raised $ 92.9m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Array BioPharma
HQ
Boulder, US
Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
View companyObsEva
HQ
Plan-les-Ouates, CH
Employees
8↓ 11% decrease
ObsEva is a speciality biopharmaceutical company developing drugs for womens reproductive medicine.
View companyAffimed N.V.
HQ
Heidelberg, DE
Employees
76
Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
View companyAvid Bioservices
HQ
Tustin, US
Employees
211↑ 14% increase
Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company.
View company